Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrphostin Ag 490 SCHEMBL93683 | 1.00 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin Ag 490 SCHEMBL29351367 | 1.00 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin Ag 490 SCHEMBL2279210 | 1.00 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin Ag 490 SCHEMBL29379893 | 1.00 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin Ag 490 SCHEMBL17743575 | 1.00 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7378564 | 0.88 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin Ag 490 SCHEMBL2279211 | 0.88 | EGFR (0.77) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Ls-104 SCHEMBL3956490 | 0.86 | MAOB (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL645291 | 0.86 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Ls-104 SCHEMBL3956495 | 0.86 | MAOB (1.00) | EGFRMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1593 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4149548-B1 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | DISC MEDICINE INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260098088-A1 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | DISC MEDICINE, INC. (US) | 2026-04-09 | — | — | US | claimed |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | BIO THERA SOLUTIONS LTD (CN) | 2025-12-18 | — | — | US | claimed |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2025-10-30 | — | — | US | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-21 | — | — | US | claimed |
| US-20250255857-A1 | METHODS OF TREATING ANDROGEN RECEPTOR-INDEPENDENT PROSTATE CANCER | FOGHORN THERAPEUTICS INC. | 2025-08-14 | — | — | US | claimed |
| EP-1482983-A4 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2006-07-12 | — | — | EP | claimed |
| EP-1482983-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-12-08 | — | — | EP | claimed |
| US-20040197335-A1 | Non-myeloablative tolerogenic treatment with tyrphostins | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-10-07 | — | — | US | claimed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| WO-2003065971-A9 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2003-11-20 | — | — | WO | claimed |
| WO-2003065971-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-08-14 | — | — | WO | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020156023-A1 | Lometrexol combination therapy | TULARIK INC. | 2002-10-24 | — | — | US | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| WO-2002045717-A1 | LOMETREXOL COMBINATION THERAPY | TULARIK INC. (US) | 2002-06-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255857-A1 | METHODS OF TREATING ANDROGEN RECEPTOR-INDEPENDENT PROSTATE CANCER | AR, ESRRB, ESRRA | EGFR 289/4885MEN1 2658/4885KMT2A 587/4885 |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | NECTIN4, VSIG8, IGSF11 | EGFR 1917/4885MEN1 1693/4885KMT2A 3457/4885 |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | NECTIN4, CD22, NGFR | EGFR 467/4885MEN1 1105/4885KMT2A 3881/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | EGFR 2486/4885MEN1 3673/4885KMT2A 1605/4885 |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CNTN1, EPCAM, SLC22A8 | EGFR 1984/4885MEN1 2360/4885KMT2A 1685/4885 |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | TPM4, TPM3, TPST2 | EGFR 250/4885MEN1 2103/4885KMT2A 871/4885 |
| US-20260098088-A1 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | HAMP, IGLV6-57, ETV6 | EGFR 1250/4885MEN1 1925/4885KMT2A 1111/4885 |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | FCGR2A, FCGR1A, FCGR3B | EGFR 49/4885MEN1 1874/4885KMT2A 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.